keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy neuropathy

keyword
https://www.readbyqxmd.com/read/29221445/study-protocol-of-hgcsg1404-snow-study-a-phase-i-ii-trial-of-combined-chemotherapy-of-s-1-nab-paclitaxel-and-oxaliplatin-administered-biweekly-to-patients-with-advanced-gastric-cancer
#1
Yasuyuki Kawamoto, Yoshito Komatsu, Satoshi Yuki, Kentaro Sawada, Tetsuhito Muranaka, Kazuaki Harada, Hiroshi Nakatsumi, Hiraku Fukushima, Atsushi Ishiguro, Masayoshi Dazai, Kazuteru Hatanaka, Michio Nakamura, Ichiro Iwanaga, Minoru Uebayashi, Susumu Sogabe, Yoshimitsu Kobayashi, Takuto Miyagishima, Kota Ono, Naoya Sakamoto, Yuh Sakata
BACKGROUND: In Japan, S-1 plus cisplatin (SP) regimen has become a standard therapy for patients with advanced gastric cancer. Moreover, the S-1 plus oxaliplatin regimen is now a standard treatment. Nab-paclitaxel was developed for chemotherapy of gastric cancer in Japanese clinical practice. Nab-paclitaxel, created with albumin-bound paclitaxel particles, has high transferability to tumour tissues and does not cause hypersensitivity reactions because of a different chemical composition compared with docetaxel and paclitaxel...
December 8, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29219049/role-of-mitochondrial-mechanism-in-chemotherapy-induced-peripheral-neuropathy
#2
Mohammad Waseem, Pooja Kaushik, Heena Tabassum, Suhel Parvez
BACKGROUND: Even though chemotherapeutic regimens shows considerable importance, it may cause progressive, continuing and sometimes irreversible peripheral neuropathy. Chemotherapy induced peripheral neuropathy (CIPN) comprises of sensory abnormalities that are most distress issues. The mechanism associated with CIPN pathogenesis is not completely revealed and is treatment is still questionable. The purpose of this review was to investigate the role of mitochondria in CIPN. METHODS: This review is literature based that describes the mitochondrial mechanism underlying CIPN and the neuropathic complications associated with different antineoplastic agents...
December 7, 2017: Current Drug Metabolism
https://www.readbyqxmd.com/read/29206213/duloxetine-protects-against-oxaliplatin-induced-neuropathic-pain-and-spinal-neuron-hyperexcitability-in-rodents
#3
Woojin Kim, Yeongu Chung, Seunghwan Choi, Byung-Il Min, Sun Kwang Kim
Oxaliplatin is a widely used chemotherapy agent, but induces serious peripheral neuropathy. Duloxetine is a dual reuptake inhibitor of serotonin and norepinephrine, and is shown to be effective against pain. However, whether and how duloxetine can attenuate oxaliplatin-induced allodynia in rodents is not clearly understood. A single injection of oxaliplatin (6 mg/kg, intraperitoneal; i.p.) induced a cold and mechanical allodynia, which was assessed by acetone and von Frey filament tests, respectively. When significant allodynic signs were observed, three different doses of duloxetine (10, 30, and 60 mg/kg, i...
December 5, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29204710/chemotherapy-related-neuropathic-symptom-management-a-randomized-trial-of-an-automated-symptom-monitoring-system-paired-with-nurse-practitioner-follow-up
#4
Noah Allan Kolb, Albert Gordon Smith, John Robinson Singleton, Susan L Beck, Diantha Howard, Kim Dittus, Summer Karafiath, Kathi Mooney
PURPOSE: The purpose of this study was to evaluate a new care model to reduce chemotherapy-induced neuropathic symptoms. Neuropathic symptom usual care was prospectively compared to an automated symptom-monitoring and coaching system, SymptomCare@Home (SCH), which included nurse practitioner follow-up triggered by moderate to severe symptoms. METHODS: Patients beginning chemotherapy were randomized to usual care (UC) or to the SCH intervention. This sub-analysis included only taxane/platin therapies...
December 5, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29198853/effects-of-exercise-on-cancer-patients-suffering-chemotherapy-induced-peripheral-neuropathy-undergoing-treatment-a-systematic-review
#5
REVIEW
Federica Duregon, Barbara Vendramin, Valentina Bullo, Stefano Gobbo, Cugusi Lucia, Andrea Di Blasio, Daniel Neunhaeuserer, Marco Zaccaria, Marco Bergamin, Andrea Ermolao
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is the most common neurological and clinically relevant side effect of many commonly used chemotherapeutic agents. Moreover, little effort has been done to investigate the potentially beneficial effects of specific exercises to counteract the CIPN symptoms. OBJECTIVE: This document aims to summarize and analyze systematically the current body of evidence about the effects of specific exercise protocols on CIPN symptoms, balance control, physical function and quality of life in patients with CIPN...
November 7, 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29198326/the-molecular-genetics-of-chemotherapy-induced-peripheral-neuropathy-a-systematic-review-and-meta-analysis
#6
REVIEW
J Cliff, A L Jorgensen, R Lord, F Azam, L Cossar, D F Carr, M Pirmohamed
Chemotherapy-induced peripheral neuropathy (CIPN) can adversely affect completion of systemic anti-cancer treatment and cause long-term morbidity. Increasingly pharmacogenetic studies have been performed to explore susceptibility to this important adverse effect. A systematic review was conducted to identify pharmacogenetic studies, assess their quality and findings and undertake meta-analysis where possible. 93 studies were included. Notable methodological issues included lack of standardisation and detail in phenotype definition and acknowledgement of potential confounding factors...
December 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29197621/inhibition-of-histone-deacetylase-6-hdac6-protects-against-vincristine-induced-peripheral-neuropathies-and-inhibits-tumor-growth
#7
Lawrence Van Helleputte, Mandy Kater, Dana P Cook, Caroline Eykens, Elisabeth Rossaert, Wanda Haeck, Tom Jaspers, Natasja Geens, Pieter Vanden Berghe, Conny Gysemans, Chantal Mathieu, Wim Robberecht, Philip Van Damme, Guido Cavaletti, Matthew Jarpe, Ludo Van Den Bosch
As cancer is becoming more and more a chronic disease, a large proportion of patients is confronted with devastating side effects of certain anti-cancer drugs. The most common neurological complications are painful peripheral neuropathies. Chemotherapeutics that interfere with microtubules, including plant-derived vinca-alkaloids such as vincristine, can cause these chemotherapy-induced peripheral neuropathies (CIPN). Available treatments focus on symptom alleviation and pain reduction rather than prevention of the neuropathy...
November 29, 2017: Neurobiology of Disease
https://www.readbyqxmd.com/read/29196945/pain-in-platin-induced-neuropathies-a-systematic-review-and-meta-analysis
#8
REVIEW
Vasiliki Brozou, Athina Vadalouca, Panagiotis Zis
INTRODUCTION: Platin-induced peripheral neuropathy (PIPN) is a common cause of PN in cancer patients. The aim of this paper is to systematically review the current literature regarding PIPN, with a particular focus on epidemiological and clinical characteristics of painful PIPN, and to discuss relevant management strategies. METHODS: A systematic computer-based literature search was conducted on the PubMed database. RESULTS: This search strategy resulted in the identification of 353 articles...
December 1, 2017: Pain and Therapy
https://www.readbyqxmd.com/read/29196027/cancer-chemotherapy-in-early-life-significantly-alters-the-maturation-of-pain-processing
#9
G J Hathway, Emily Murphy, Joseph Lloyd, Charles Greenspon, R P Hulse
Advances in paediatric cancer treatment have led to a ten year survival rate greater than 75%. Platinum-based chemotherapies (e.g.cisplatin) induce peripheral sensory neuropathy in adult and paedriatric cancer patients. The period from birth through to adulthood represents a period of maturation within nociceptive systems. Here we investigated how cisplatin impacts upon postnatal maturation of nociceptive systems. Neonatal Wistar rats (Postnatal day (P) 7) were injected (i.p.) daily with either vehicle (PBS) or cisplatin (1mg/kg) for five consecutive days...
November 28, 2017: Neuroscience
https://www.readbyqxmd.com/read/29194564/oxaliplatin-induced-enteric-neuronal-loss-and-intestinal-dysfunction-is-prevented-by-co-treatment-with-bgp-15
#10
Rachel M McQuade, Vanesa Stojanovska, Rhian Stavely, Cara Timpani, Aaron C Petersen, Raquel Abalo, Joel C Bornstein, Emma Rybalka, Kulmira Nurgali
BACKGROUND AND PURPOSE: Gastrointestinal side-effects of chemotherapy are under-recognised clinical hurdle leading to dose reduction, delays and cessation of treatment, presenting a constant challenge for efficient and tolerable anti-cancer treatment. We have previously found that oxaliplatin treatment results in intestinal dysfunction, oxidative stress and loss of enteric neurons. BGP-15 is a novel cytoprotective compound with potential HSP72 co-inducing and PARP inhibiting properties...
November 30, 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/29192128/zinc-inhibits-trpv1-to-alleviate-chemotherapy-induced-neuropathic-pain
#11
Jialie Luo, Alexis Bavencoffe, Pu Yang, Jing Feng, Shijin Yin, Aihua Qian, Weihua Yu, Shenbin Liu, Xuan Gong, Tao Cai, Edgar T Walters, Carmen W Dessauer, Hongzhen Hu
Zinc is a transition metal that has a long history of use as an anti-inflammatory agent. It also soothes pain sensations in a number of animal models. However, the effects and mechanisms of zinc on chemotherapy-induced peripheral neuropathy (CIPN) remain unknown. Here we show that locally injected zinc markedly reduces neuropathic pain in male and female mice induced by paclitaxel, a chemotherapy drug, in a TRPV1-dependent manner. Extracellularly applied zinc also inhibits the function of TRPV1 expressed in HEK293 cells and mouse DRG neurons, which requires the presence of zinc-permeable TRPA1 to mediate entry of zinc into the cytoplasm...
November 30, 2017: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/29191802/peripheral-neuropathy-induced-by-microtubule-targeted-chemotherapies-insights-into-acute-injury-and-long-term-recovery
#12
Krystyna M Wozniak, James J Vornov, Ying Wu, Ying Liu, Valentina A Carozzi, Virginia Rodriquez-Menendez, Elisa Ballarini, Paola Alberti, Eleonora Pozzi, Sara Semperboni, Brett M Cook, Bruce A Littlefield, Kenichi Nomoto, Krista Condon, Sean Eckley, Christopher DesJardins, Leslie Wilson, Mary Ann Jordan, Stuart C Feinstein, Guido Cavaletti, Michael Polydefkis, Barbara S Slusher
Chemotherapy-induced peripheral neuropathy (CIPN) is a major cause of disability in cancer survivors. CIPN investigations in preclinical model systems have focused on either behaviors or acute changes in nerve conduction velocity (NCV) and amplitude, but greater understanding of the underlying nature of axonal injury and its long-term processes is needed as cancer patients live longer. In this study, we used multiple independent endpoints to systematically characterize CIPN recovery in mice exposed to the anti-tubulin cancer drugs eribulin (ERIB), ixabepilone (IXA), paclitaxel (PACLI) or vinorelbine (VINO) at maximal tolerated doses...
November 30, 2017: Cancer Research
https://www.readbyqxmd.com/read/29187478/the-relationship-between-peripheral-neuropathy-induced-by-docetaxel-and-systemic-inflammation-based-parameters-in-patients-with-breast-cancer
#13
Kosho Yamanouchi, Sayaka Kuba, Chika Sakimura, Michi Morita, Kengo Kanetaka, Kazuma Kobayashi, Mitsuhisa Takatsuki, Naomi Hayashida, Susumu Eguchi
BACKGROUND/AIM: Docetaxel often induces peripheral neuropathy (PN). The aim of this study was to elucidate the relationship between PN and systemic inflammation parameters, namely the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR). PATIENTS AND METHODS: We retrospectively evaluated 67 patients with breast cancer who were treated with docetaxel. Thirty patients (44.8%) had received previous chemotherapy including anthracycline...
December 2017: Anticancer Research
https://www.readbyqxmd.com/read/29184694/survivorship-after-treatment-of-pancreatic-cancer-insights-via-an-internet-based-survivorship-care-plan-tool
#14
REVIEW
Melissa A Frick, Carolyn C Vachani, Margaret K Hampshire, Christina Bach, Karen Arnold-Korzeniowski, James M Metz, Christine E Hill-Kayser
Pancreatic cancer survivors face a unique set of challenges in survivorship, yet structured survivorship care planning is lacking in practice. Survivorship care plans (SCPs) are an essential part of quality cancer care and can facilitate the transition following active treatment; the use of SCPs in pancreatic cancer survivors, however, has not been explored. With a convenience sample of 117 pancreatic cancer survivors and proxies who used an Internet-based SCP tool, we examined treatment details, patient-reported outcomes, and survivorship practices...
October 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29183032/return-to-work-of-cancer-survivors
#15
Ulf Seifart, Jan Schmielau
Due to improving treatment options, the number of so-called long-term cancer survivors is steadily increasing. Current studies assume that more than 60% of adults survive their cancer. These patients have a variety of problems (chemotherapy-induced neuropathy, fatigue, etc.) that require very special care. In addition to somatic and psychological side effects of the cancer or its treatment, these patients also suffer from the financial and social consequences of the disease. Thus, for a long-term survivor of working age, the question of a 'return to work' represents a significant problem since otherwise the financial existence of the patient, and often the family, may substantially deteriorate...
2017: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29177608/identification-of-educational-gaps-among-oncologists-who-manage-patients-with-pancreatic-cancer
#16
Justin A Barnes, Melissa L Ellis, Sharon Hwang, Joan Emarine, Patti Merwin, Gregory D Salinas, Benjamin L Musher
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDA) is associated with poor outcomes and presents oncologists with a myriad of clinical challenges. This study was conducted to assess oncologists' practice patterns and to identify the greatest areas of need for future PDA continuing medical education (CME) programs. METHODS: Case vignettes have been validated as an effective tool to assess how physicians approach and treat a wide array of diseases. In order to assess practice patterns for resectable, locally advanced unresectable, and metastatic PDA, an online case vignette survey was distributed to practicing medical oncologists...
November 27, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/29173976/phase-2-study-of-weekly-paclitaxel-plus-estramustine-in-metastatic-hormone-refractory-prostate-carcinoma-ecog-acrin-cancer-research-group-e1898-trial
#17
Yu-Ning Wong, Judith Manola, Gary R Hudes, Bruce J Roth, Judd W Moul, Andrea M Barsevick, Richard M Scher, Michael J Volk, David J Vaughn, Stephen D Williams, Michael J Fisch, David Cella, Michael A Carducci, George Wilding
INTRODUCTION: This multicenter phase 2 study assessed the combination of estramustine and weekly paclitaxel with metastatic castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: We enrolled 77 patients who had received no prior chemotherapy for CRPC between 1998 and 2000; a total of 74 subjects were eligible for the study. Each 8-week cycle included paclitaxel 90 mg/m2 provided intravenously weekly for 6 weeks, followed by 2 weeks off therapy and oral estramustine 280 mg twice daily for 3 days beginning 24 hours before the first dose of paclitaxel...
October 16, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29173832/the-psychometric-properties-of-the-turkish-version-of-the-chemotherapy-induced-peripheral-neuropathy-assessment-tool-cipnat
#18
Sevinç Kutlutürkan, Elif Sözeri Öztürk, Fatma Arıkan, Burcu Bayrak Kahraman, Keziban Özcan, Mürvet Artuk Uçar
PURPOSE: Chemotherapy-induced peripheral neuropathy is a common treatment-related adverse effect. It adversely affects the quality of life. Therefore, it is important to evaluate symptoms. The purpose of this study was to evaluate the validity and reliability of Chemotherapy-Induced Peripheral Neuropathy Assessment Tool in Turkish patients. METHODS: A convenience sample of 327 patients, being treated with peripheral neurotoxic chemotherapeutic agents were asked to fill in the questionnaire...
December 2017: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://www.readbyqxmd.com/read/29169873/modified-hypercvad-versus-bortezomib-hypercad-in-patients-with-relapsed-refractory-multiple-myeloma
#19
Megan M Saraceni, Emma Scott, Richard T Maziarz, Matthew B Siegel, Solange Bassale, Susie Jiing, Eva Medvedova
INTRODUCTION: Multiple myeloma (MM) is an incurable plasma cell malignancy, in which aggressive relapses might require salvage cytotoxic infusional chemotherapy. Several clinical trials that reported the efficacy of bortezomib led to institutional practice changes in which vincristine was replaced with bortezomib in the modified hyperCVAD regimen, creating a new treatment regimen, named "bortezomib-hyperCAD." PATIENTS AND METHODS: We retrospectively describe the effectiveness and tolerability of 2 chemotherapy regimens among 33 patients with relapsed and/or refractory MM...
November 2, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29169431/monoclonal-igm-gammopathy-and-waldenstr%C3%A3-m-s-macroglobulinemia
#20
Alexander Grunenberg, Christian Buske
BACKGROUND: 3.2-3.5% of persons over age 50 have a monoclonal gammopathy. Monoclonal gammopathies have many causes, including cancer. 10-20% of monoclonal gammopathies are of isotype IgM. A systematic approach to the differential diagnosis of IgM gammopathies is essential because of the different therapeutic implications of the various underlying conditions. METHODS: This review is based on pertinent publications retrieved by a selective search in PubMed and current guidelines from Germany and abroad...
November 3, 2017: Deutsches Ärzteblatt International
keyword
keyword
70500
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"